Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
” Wow! What a surprise!
Deeply honored to receive the Indo-American-Cancer-Association (IACA) Award at ASCO26 annual meeting Chicago, 2026 for Outstanding Contributions to Drug Development & Pioneering Advances in Clinical Cancer Research.
- This recognition means so much not just as a personal milestone, but as a reflection of the incredible VILLAGE that makes this work possible
- Mentors who shaped MY thinking + collaborators who challenged & inspired me + Patients who trusted me with their care + friends & family who anchored me through it all.
- Thank you to the IACA leadership for this honor.”
Other articles featuring Vivek Subbiah on OncoDaily.